Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Saved in:
Bibliographic Details
Title: Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Authors: Gandhi UH; Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Cornell RF; Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Lakshman A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gahvari ZJ; University of Wisconsin, Madison, WI, USA., McGehee E; University of Texas Southwestern Medical Center, Dallas, TX, USA., Jagosky MH; Department of Hematologic Oncology & Blood Disorders Levine Cancer Institute/Carolinas Health Care, Charlotte, NC, USA., Gupta R; Stanford Cancer Institute, Stanford, CA, USA., Varnado W; Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA., Fiala MA; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA., Chhabra S; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Malek E; Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Mansour J; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Paul B; Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA., Barnstead A; Oregon Health & Science University, Portland, OR, USA., Kodali S; University of Vermont, College of Medicine, Burlington, VT, USA., Neppalli A; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Liedtke M; Stanford Cancer Institute, Stanford, CA, USA., Narayana S; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Godby KN; Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA., Kang Y; Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA., Kansagra A; University of Texas Southwestern Medical Center, Dallas, TX, USA., Umyarova E; University of Vermont, College of Medicine, Burlington, VT, USA., Scott EC; Oregon Health & Science University, Portland, OR, USA., Hari P; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Vij R; Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA., Usmani SZ; Department of Hematologic Oncology & Blood Disorders Levine Cancer Institute/Carolinas Health Care, Charlotte, NC, USA., Callander NS; University of Wisconsin, Madison, WI, USA., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Costa LJ; Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. ljcosta@uabmc.edu.
Source: Leukemia [Leukemia] 2019 Sep; Vol. 33 (9), pp. 2266-2275. Date of Electronic Publication: 2019 Mar 11.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-019-0435-7